Author:
Guo Caiping,Liu Kewei,Zheng Yi,Luo Haibo,Chen Hongbo,Huang Laiqiang
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry, medical,Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference39 articles.
1. Schiffman MH, Brinton LA (1995) The epidemiology of cervical carcinogenesis. Cancer 76(10 Suppl):1888–1901
2. Chunlian N, Guolan G, Jie H, Hua L, Heping C, Ming H (2008) Human papillomavirus 16 E6, E7 siRNAs inhibit proliferation and induce apoptosis of SiHa cervical cancer cells. Chin J Cancer Res 20(4):6
3. Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R (2008) HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology 375(2):611–623
4. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA (2000) Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121(2):216–225
5. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A et al (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8(12):3676–3685
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献